Harrow, INC 8-K filings

Harrow, Inc. reported a significant sequential revenue increase of 60% for Q2 2026, driven by strong performance in VEVYE and IHEEZO, and reiterated full-year guidance.

Harrow, Inc. announced its definitive agreement to acquire the global rights to TYRVAYA (varenicline solution) nasal spray from Viatris Inc., expanding its dry eye disease portfolio.

Harrow, Inc. has released a corporate presentation dated June 2026, intended for investor relations and outlining company information.

Harrow, Inc. announced its first quarter 2026 financial results, highlighting strong demand for key products like VEVYE, IHEEZO, and TRIESENCE, while addressing a non-recurring revenue adjustment impacting reported figures.

Harrow, Inc. announced the issuance of an additional $50 million in 8.625% Senior Notes due 2030 to fund general corporate purposes and growth initiatives.

Harrow, Inc. announced the pricing of a $50.0 million private offering of additional 8.625% Senior Notes due 2030 to fund general corporate purposes and growth initiatives.

Harrow, Inc. announced a private offering of $50.0 million in 8.625% Senior Notes due 2030 to fund growth initiatives and product development.

Harrow, Inc. announced record fourth quarter and full-year 2025 financial results, driven by strong growth in key ophthalmic products and provided optimistic 2026 financial guidance.

Harrow, Inc. reaffirmed its full-year 2025 revenue guidance and announced the promotion of Patrick W. Sullivan to Chief Commercial Officer.

Harrow, Inc. has completed its acquisition of Melt Pharmaceuticals, expanding its portfolio with non-opioid, non-IV sedation therapies.

Harrow, Inc. announced a 45% increase in Q3 2025 revenues to $71.6 million, driven by strong performance from VEVYE and IHEEZO, while adjusting full-year guidance due to underperforming products and an inventory shortage.

Harrow, Inc. announced leadership changes at its wholly-owned subsidiary, ImprimisRx, appointing Frank Mullery as CEO and Bridseida Cruz as Head of Quality.

Harrow, Inc. is set to acquire Melt Pharmaceuticals, Inc., a clinical-stage company focused on procedural sedation for cataract surgery, through a merger agreement that includes upfront cash and significant milestone payments.

Harrow, Inc. has entered into a new $40 million senior secured revolving credit facility with Fifth Third Bank, National Association, maturing in 2030.

Harrow, Inc. announced it hosted an Investor Day on September 26, 2025, and furnished the investor presentation used at the event.

Harrow, Inc. has entered into a definitive merger agreement to acquire the remaining equity interests in Melt Pharmaceuticals, Inc., expanding its portfolio with a non-opioid procedural sedation therapy.

Harrow, Inc. announced the dismissal of Crowe LLP and the appointment of Deloitte & Touche LLP as its new independent registered public accounting firm.

Harrow, Inc. has completed a private offering of $250 million in 8.625% Senior Notes due 2030 and announced the full redemption of its 2026 and 2027 Senior Notes.

Harrow, Inc. announced the pricing of a $250 million private offering of 8.625% senior unsecured notes due 2030, primarily to refinance existing debt.

Harrow, Inc. announced a $250 million senior unsecured notes offering, a new $40 million revolving credit facility, and plans to redeem existing debt, alongside a potential acquisition of Melt Pharmaceuticals.

Harrow, Inc. announced key executive appointments and updated corporate bylaws to enhance governance and financial oversight.

Harrow, Inc. announced a 30% increase in Q2 2025 revenues to $63.7 million, alongside strategic acquisitions and positive product momentum.

Harrow, Inc. has entered into an agreement with Samsung Bioepis to gain exclusive U.S. commercial rights for BYOOVIZ and OPUVIZ, two leading ophthalmology biosimilars, significantly expanding its market presence in retinal disease treatments.

Harrow, Inc. announced that all five proposals submitted to a binding vote of stockholders at its 2025 Annual Meeting were approved, including the election of four directors and the adoption of a new incentive stock and awards plan.

Harrow, Inc. has entered into an exclusive licensing agreement with Formosa Pharmaceuticals for the U.S. commercial rights to BYQLOVI, an FDA-approved ophthalmic steroid for post-operative inflammation and pain following ocular surgery.

Harrow Inc. reports a 38% increase in first-quarter revenue, driven by strong VEVYE sales growth and the launch of the VEVYE Access for All program.

Harrow Inc. reports record Q4 and full-year 2024 revenues, driven by strong performance of key products like IHEEZO and VEVYE, and issues optimistic 2025 revenue guidance.

Harrow, Inc. reports unaudited preliminary financial results for Q4 and year-end 2024, provides 2025 revenue guidance, and announces a delay in the release of audited financial results due to additional time needed by the new independent auditor.

Harrow Inc. announces the resignation of board member Marty A. Makary, leading to a reduction in the board's size.

Harrow Inc. announced a 44% year-over-year revenue increase for the third quarter of 2024, driven by strong demand for key products and strategic market initiatives.